Our team has also previously demonstrated that the aberrant expression of DUX4/IGH in B-ALL patients and the subsequent abnormal alternative splicing it drives, namely ERGalt, are primary driving factors for the comprehensive onset of leukemia, establishing ERGalt as a significant secondary hit in leukemia development13. Here, DUX4 is linked to leukemia.